The Application of DNA Nanomachines for Detecting microRNA in Blood for the Diagnosis of Pancreatic Cancer. Diagnosis of Pancreatic Cancer

The Application of DNA Nanomachines for Detecting microRNA in Blood for the Diagnosis of Pancreatic Cancer.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06497777

Enrollment

Registered

2024-07-12

Start date

2024-07-06

Completion date

2026-06-01

Last updated

2024-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MicroRNA, Pancreas Adenocarcinoma

Keywords

MicroRNA, Pancreas Adenocarcinoma

Brief summary

Previous research has shown that microRNAs in the blood can serve as biomarkers for early pancreatic cancer, with potential applications including detection, differential diagnosis, and prognosis prediction of pancreatic cancer. The current primary method for detecting microRNAs is RT-qPCR, but this process requires repeated temperature cycling, which demands high precision from the equipment. As an alternative, isothermal nucleic acid amplification technology does not require expensive temperature control instruments. Our research team has developed various isothermal nucleic acid amplification strategies for microRNA sensing platforms, applied to biological sample detection. This study combines the circular strand displacement amplification strategy with DNA nanomachines to develop a fluorescence sensing platform that performs dual signal amplification at a constant temperature. It is designed to detect pancreatic cancer-related microRNAs, exploring its role and potential applications in the diagnosis of pancreatic cancer patients.

Interventions

GENETICMicroRNA (mir-642b-3p)

A circulating microRNA in the blood of pancreatic cancer patients.

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Pancreatic ductal adenocarcinoma * Proven by pathology * Patients who have not received anti-cancer therapies

Exclusion criteria

* Less than 20 years old * Unable to provide inform and consent * Patients who have active malignancy other than pancreatic adenocarcinoma * Patients who have had pancreatic cancer whose anti-cancer therapies are completed or undergoing * Life expectancy less than 3 months

Design outcomes

Primary

Measure	Time frame
Ratio of the target microRNA in patients with and without pancreatic adenocarcinoma.	24 hours

Countries

Taiwan

Contacts

Primary ContactWeng Fai Wong, Master of Science

106290@ntuh.gov.tw886-972652272

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026